According to Dilip Bhat, Joint MD of Prabhudas Lilladher, Ranbaxy still looks reasonably available at the current levels. It is a good investment bet, he adds.

Ranbaxy Laboratories may test Rs 430: SP Tulsian

SP Tulsian of sptulsian.com feels that Ranbaxy Laboratories can test Rs 430 in this series or may be in next couple of weeks.

Ranbaxy can give high returns but extremely risky: Dron Cap

Pathik Gandotra of Dron Capital feels Ranbaxy Labs can also give a very high return, but it is extremely risky, he adds.

Ranbaxy Laboratories may test Rs 380: Rajesh Agarwal

Rajesh Agarwal of Eastern Financiers is of the view that Ranbaxy Laboratories may test Rs 380 in the medium term.

Brokerage calls: Buy TCS, M&M, ICICI Bank, Ranbaxy

Brokerages advise buying Ranbaxy, TCS, Mahindra & Mahindra, ICICI Bank.

Ranbaxy Laboratories may touch Rs 390, says SP Tulsian

SP Tulsian of sptulsian.com is of the view that Ranbaxy Laboratories may touch Rs 390 in a week. "The delivery percentage today will be very crucial to watch out for because the strong hands which have entered into the stock seems to have come back in their second inning," he adds.

Ranbaxy Laboratories may test Rs 365-370, says Baliga

According to Ambareesh Baliga of Edelweiss, Ranbaxy Laboratories may test Rs 365-370.

Buy DLF, Ranbaxy, Axis Bank: SP Tulsian

SP Tulsian of sptulsian.com recommends buying DLF with a target of Rs 139 and a stoploss of Rs 134 and Indiabulls Real Estate with a target of Rs 57 and a stoploss of Rs 55.50.

Buy Ranbaxy Laboratories at around Rs 240-260: Kulkarni

Shardul Kulkarni of Angel Broking recommends to exit Ranbaxy Laboratories at these prices and probably look at buying around Rs 260-240.

Here's how to trade M&M, Bajaj Auto, Ranbaxy today

BofA ML believes Ranbaxy will underperform with a target price of Rs 320. According to them, the resolution of USFDA will take longer than expected which will lead to delay in new product approvals and that is likely to impact growth. The brokerage sees limited visibility on its US product pipeline.

Ranbaxy Laboratories may test Rs 360-365: SP Tulsian

SP Tulsian of sptulsian.com is of the view that Ranbaxy Laboratories may test Rs 360-365.

Ranbaxy Laboratories may test Rs 380: SP Tulsian

SP Tulsian of sptulsian.com feels that Ranbaxy Laboratories may test Rs 380 by this month expiry.

Ranbaxy Labs may test Rs 375-380: SP Tulsian

According to SP Tulsian of sptulsian.com, Ranbaxy Laboratories may touch Rs 375-380 in the near term.

Don't see much value in Ranbaxy; growth prospects dim: IIFL

This year, Ranbaxy may post about Rs 7-8 earnings per share (EPS) from their core business, says Bino Pathiparampil of IIFL.

Hold Ranbaxy Laboratories: SP Tulsian

SP Tulsian of sptulsian.com is of the view that one can hold Ranbaxy Laboratories. He expects the share to move to a level of Rs 360 in next 8-10 days.

Ranbaxy may bounce back to Rs 360-370: SP Tulsian

SP Tulsian of sptulsian.com feels that Ranbaxy Laboratories may bounce back to Rs 360-370 in September series itself. “There is very limited risk of going down from here and Rs 320 seems to be a good support for the stock,” he adds.

Lupin may touch Rs 885-890, says SP Tulsian

According to SP Tulsian of sptulsian.com, Lupin may touch Rs 885-890. “The company received the USFDA approval for launch of the generic version of the Sanofi‘s Ambien, which is for curing of insomnia and it has USD 400 million markets,” he adds.

Avoid Ranbaxy Laboratories, advises Ambareesh Baliga

Ambareesh Baliga, Managing Partner-Global Wealth Management of Edelweiss Financial Services is of the view that one may avoid Ranbaxy Laboratories.

Ranbaxy may test Rs 250-260: Shardul Kulkarni

Shardul Kulkarni of Angel Broking is of the view that Ranbaxy Laboratories may touch Rs 250-260 in the next one to one and half months.

Exit Ranbaxy Laboratories, says Phani Sekhar

Phani Sekhar of Angel Broking suggests to exit from Ranbaxy Laboratories.

Sell Ranbaxy Laboratories on rally: Nooresh Merani

According to Nooresh Merani of AMSEC Research, one may sell Ranbaxy Laboratories on rally.

Avoid Ranbaxy Laboratories: Sudarshan Sukhani

According to Sudarshan Sukhani of s2analytics.com, one may avoid Ranbaxy Laboratories.

Impact of FDA import alert on Ranbaxy sentimental: Expert

If the companies' exclusivities which are still in the pipeline like Diovan and Valcyte are from this plant then there can be significant financial impact, says Sriram Rathi.

Buy BPCL, Ranbaxy, Eicher Motors on dip: Rakesh Arora

Rakesh Arora of Macquarie Capital Securities recommends buying Bharat Petroleum Corporation (BPCL), Ranbaxy Laboratories and Eicher Motors on correction.

BHEL may test Rs 132-135, says Aditya Agarwal

Aditya Agarwal of Way2Wealth is of the view that Ranbaxy Laboratories may test Rs 480 on the higher side. "Bharat Heavy Electricals (BHEL) on technical side is giving a breakout from its inverse head and shoulder pattern and we are expecting that the stock may test Rs 132-135 on higher side," he adds.